轉移性乳腺癌重磅研究一覽

一年一度的全球腫瘤界盛會-美國臨床腫瘤學會（ASCO）年會將于當地時間6月3日-6月7日召開。醫脈通特梳理了轉移性乳腺癌領域的部分重磅研究進展。一起來看下吧！

全體大會

標題：Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.

報告人：Shanu Modi, MD

單位：Memorial Sloan Kettering Cancer Center

口頭報告

標題：Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.

報告人：Erika P. Hamilton, MD

單位：Sarah Cannon Research Institute/Tennessee Oncology

標題：Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.

報告人：Hope S. Rugo, MD, FASCO

單位：Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center

標題：Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

報告人：Ian E. Krop, MD, PhD

單位：Dana-Farber Cancer Institute

標題：Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2? ABC): Analyses from PALOMA-2.

報告人：Richard S. Finn, MD

單位：David Geffen School of Medicine at UCLA

標題：A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.

報告人：Kevin Kalinsky, MD, MS

單位：Winship Cancer Institute, Emory University

標題：Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.

報告人：Robert Hugh Jones, PhD, FRCP

單位：Velindre Cancer Centre and School of Medicine Cardiff University

標題：Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2?) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.

報告人：Dejan Juric, MD

單位：Massachusetts General Hospital Cancer Center, Harvard Medical School

標題：NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).

報告人：Steven J. Chmura, MD, PhD

單位：The University of Chicago Medicine

標題：Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S. women, 2000-2017.

報告人：Jennifer Lee Caswell-Jin, MD, BA

單位：Stanford University

壁報討論

標題：Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.

報告人：Dejan Juric, MD

單位：Massachusetts General Hospital Cancer Center, Harvard Medical School

標題：Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2? breast cancer and an ESR1 mutation after progression on prior therapies.

報告人：Senthil Damodaran, MD, PhD

單位：The University of Texas MD Anderson Cancer Center

標題：A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.

報告人：Philippe Georges Aftimos, MD

單位：Institut Jules Bordet, Université Libre de Bruxelles

標題：Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010).

報告人：Alistair E. Ring, MD, MRCP, MA

單位：The Royal Marsden NHS Foundation Trust

壁報展示

標題：Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis.

報告人：Hao Liao

單位：北京大學腫瘤醫院

標題：Ovarian function suppression is not indispensable in patients with early breast cancer who are older than age 40.

報告人：Jianqiao Xian, MD

單位：中山大學腫瘤防治中心

標題：Peripheral lipidomics analyses with ensemble machine learning predict response to neoadjuvant therapy in breast cancer.

報告人：王佳妮

單位：中國醫學科學院北京協和醫學院

標題：Primary analysis of MUKDEN 01: A multicenter, single-arm, prospective, phase 2 study of neoadjuvant treatment with pyrotinib and letrozole plus dalpiciclib in triple-positive breast cancer.

報告人：牛楠

單位：中國醫科大學附屬盛京醫院

標題：Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.

報告人：羅靜

單位：四川省醫學科學院·四川省人民醫院

標題：Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low–expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial.

報告人：Yuan Xia

單位：中山大學孫逸仙紀念醫院